Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Swedbank Robur launches a new equity fund with focus on small companies in Emerging Markets

Swedbank Robur Small Cap Emerging Markets is a new fund that invests in smaller, listed companies in Emerging Markets. This gives the fund company´s customers opportunities to invest in a previously less accessible part of the market.The new fund will focus on small companies in emerging markets, with a proven track record, established business models and strong balance sheets. Swedbank Robur Small Cap Emerging Markets is managed by Jens Barnevik, who together with his team, combines a broad experience within equity investments in small companies with an expertise in emerging markets. "

Talkpool starts IoT collaboration with StadshubbsAlliansen

Talkpool and StadshubbsAlliansen announce the collaboration, which will enable StadshubbsAlliansen’s members to cooperate with Talkpool and benefit from Talkpool’s smart city solutions.Talkpool, active in the Internet of Things (IoT) industry since 2014, is an IoT solution provider with several turnkey solutions available, for example remote water meter reading and invoicing in buildings and apartments. This allows city water management organizations and real-estate owners to individually invoice their customers on actual consumption, based on real-time data, and helps detect leakages in

NextCell continues to develop

NextCell Pharma AB ("NextCell") gives the market updated information before its presentation at ProHearing later today by CEO, Mathias Svahn. Recruitment of patients with type-1 diabetes in the Phase II part of the ProTrans-1 clinical trial with the drug candidate ProTrans is ongoing. An application for a new trial, ProTrans-repeat, has been submitted and Cellaviva's customer inflow has been increasing.ProTrans-1, NXTCL's ongoing clinical trial for the treatment of type-1 diabetes, is divided into two parts, the first being a three-step dose escalation with three patients in each step, a

The Nomination Committee’s proposal to the 2019 Annual General Meeting regarding the Board of Directors in AB Fagerhult

The Nomination Committee of AB Fagerhult (publ) has decided to propose the following to the 2019 Annual General Meeting regarding the composition of the Board of Directors. The Nomination Committee proposes new election of Annica Bresky and Teresa Enander as Board members. Furthermore, the Nomination Committee proposes re-election of the Board members Jan Svensson, Eric Douglas, Cecilia Fasth & Morten Falkenberg with the re-election of Jan Svensson  as Chairman of the Board. Fredrik Palmstierna and Catherina Fored have decided to step down from the Board and have declined re-

SUMMARY OF YEAR END REPORT 2018

View of the mine site including office building, water treatment plant, ore storage facility and plant building FOURTH QUARTER 2018 · Investments were 114 MSEK (5) · Other income was 0.1 MSEK (0) · Net profit was -42 MSEK (0) · Earnings per share was -0.32 SEK (‑0.00) · Sales agreement with Boliden for both concentrates finalised · First blast conducted on October 16th and open pit mining commenced · The construction of the tailings ponds and ore storage areas have been completed · The Company filed an application for amendments to the current

Heliospectra carries out rights issue and obtain bridge financing

GOTHENBURG, Sweden, February 22, 2019 Heliospectra AB (publ) ("Heliospectra" or "the Company"), which is listed on Nasdaq First North, announces that the Company's Board of Directors proposes a new share issue of approximately SEK 52.7 million with preferential rights for existing shareholders. The terms of the rights issue are that 3 existing shares entitle the shareholder to subscribe for 1 new share at the price of 4.5 SEK. The rights issue is 100 percent underwritten through subscription and guarantee commitments by the Company's largest shareholders, the Weland Group and Midroc.Due

ADDvise Group AB (publ) proposes directed issue to guarantors in connection with the previously oversubscribed rights issue – Regulatory information

ADDvise Group AB (publ) ("ADDvise" or the “Company") has completed the rights issue of 43,042,288 units that was announced on December 12, 2018 (the "Rights Issue"). In connection therewith, directed issues are carried out in accordance with the guarantee agreement with the guarantors of the Rights Issue who have chosen to receive guarantee remuneration in the form of shares (the "Remuneration Issues"). The subscription price in the Remuneration Issues is set at SEK 0.638 per share and payment is made through cancellation of claim. As communicated in connection with the Rights Issue, the

Year-end report 2018-01-01 – 2018-12-31

The Board and Chief Executive Officer of Cereno Scientific AB herewith present the Year-End report for 2018.Summary of the Year-End report Twelve months (2018-01-01 – 2018-12-31)●       Net sales were 0 SEK (0 SEK). ●       Loss after financial items was -11 838 887 SEK (-4 600 804 SEK). ●       Loss per share was -0,81 SEK (-0,42 SEK) before dilution and -0,54 SEK* (-0,41 SEK) after dilution. ●       Equity ratio was 63,5 % (91,3 %). Fourth quarter (2018-10-01 – 2018-12-31) ●       Net sales were 0 SEK (0 SEK). ●       Loss after financial items was -4 061 587 SEK (-

ChromoGenics receives first order for Paragon to a value of 4,5 MSEK.

Real estate company Ticon Broen AS in Norway has chosen ConverLight Paragon for the project Ticon Drammen to a value of 4,5 MSEK.With ConverLight Paragon ChromoGenics has created a façade glass that combines the unique ability of the dynamic glass to shift transparency in line after the sun light with world class insulating capacity. Those properties were highly valued by the real estate company Ticon Broen AS when they decided to place the order. Deliveries are scheduled to start May 2019. “We are very happy to get an order for the world class product Paragon as soon as two weeks after

Year-end report January-december 2018

January – December 2018 · Net asset value amounted to SEK 137.1 per share compared to SEK 111.7 at year-end 2017, which corresponds to an increase of 22.7 per cent. Net asset value per share including dividends paid of SEK 2.0 per share increased 24.5 per cent in 2018. · Bure’s net asset value was SEK 9,454M compared to SEK 7,743M at the start of the year. · Total return on the Bure share was 12.7 per cent. The SIX Return Index fell 4.4 per cent in 2018. · Consolidated profit after tax was SEK 1,821M (834). Earnings per share amounted to SEK 26.3 (12.0). Fourth quarter 2018

Accelerates in UAE – Exercise Brighter TO4 February 22–March 8.

This year has started out at high pace with great progress in UAE, further internal growth and continued market preparations. Arab Health 2019  in Dubai was a very fruitful event and the perfect opportunity to introduce Actiste to the global industry leaders and to deepen our relationships with local stakeholders, as well as initiating new relationships in the broader GCC region. Above all, we got some very encouraging words from UAE Ministry of Health and Prevention on launching our diabetes service Actiste in UAE. Due to a huge amount of

2018 Q4 report, Period October-December

Period October-December · Net sales: kSEK 0 (0) · Operating profit: kSEK -2 184 (-854) · Earnings per share: SEK -0,10 (-0,06) · Liquidity at the end of the period: kSEK 306 (2 124) Period January-December · Net sales: kSEK 0 (0) · Operating profit: kSEK -4 716 (-4 200) · Earnings per share: SEK -0,25 (-0,32) · Liquidity at the end of the period: kSEK 306 (2 124) CEO statementPanion’s epilepsy project for dogs has taken some big steps forward and I want to start with thanking all our investors for their support and trust in our idea. During the year,

Enersize receives project financing from Loudspring

Enersize Oyj (”Enersize”) has received project financing of EUR 250,000 from the major owner Loudspring Oyj (“Loudspring”), as a part of Loudspring’s growth financing program from NEFCO (Nordic Environmental Finance Corporation). The project financing is meant to establish scope for the continued development of Enersize's Chinese projects in connection with the major investment in the European market that Enersize initiated in connection with the acquisition of LEAQS during Q4 2018.The loan is issued as two non-overlapping equally large tranches of EUR 250,000. Payment of the first tranche

Enersize receives project financing from Loudspring

Loudspring has extended a 250 000 EUR loan to Enersize (Nasdaq First North ticker: ENERS). In November2018 Loudspring agreed on 2,5M EUR growth financing from the Nordic Environmental Finance Corporation(NEFCO). This loan to Enersize is the second deployment of the NEFCO funding for Loudspring and providesEnersize with resources to accelerate its internationalization. Loudspring owns 35,6% of Enersize. Full press release from Enersize can be found here: http://enersize.com/news/   About Enersize  With proprietary patent-pending automated data

Scout Gaming signs deal with Indian Playsafe Games

Scout Gaming has entered into a licensing agreement that allows the brand Scoring 11, which will be run in the same company as Indibet.com, to access Scout Gaming's full product range."This is the third customer agreement we sign where the counter-party is expected to have a significant presence in the Indian market that is growing strongly. Cricket is a huge sport locally and I’am excited about continuing to grow the liquidity network we have established. Further on this means larger prize pools and a more attractive product" comments Scout Gaming CEO, Andreas Ternström. "We see how

Full year report for 2018

Financial Highlights Initiator Pharma A/S is a Danish registered company, and is reporting its financial situation in Danish kroner (DKK). Initiator Pharma A/S was registered on May 2, 2016.  +--------------------------------------------+|Fourth Quarter (2018-10-01 – 2018-12-31) |+--------------------------------------------+| || · Net revenues were TDKK 0 (0) || · EBIT was TDKK -2,508 (-3,863) || · Earnings per share was DKK –0.00 (-0.26)|+--------------------------------------------+|

Cxense ASA – Last day of trading in subscription rights

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, HONG KONG OR SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the previous announcements by Cxense ASA (the "Company") regarding the rights issue of 12,857,142 new shares in the Company at a subscription price of NOK 7.00 per offer share (the "Rights Issue"). The

Trading of own shares as part of employee’s bonus scheme

In accordance with the stock statement of 19'th of February 2019 SpareBank 1 SR-Bank ASA has on 21 February 2019 purchased 40 000 own shares at an average price of NOK 94,0066. Total holdings of own shares after the purchase is 205 206 shares. As stated in the stock statement of 19'th of February 2019 the shares were acquired as part of SpareBank 1 SR-Bank’s bonus scheme where part of the settlement takes place through the allocation of shares. This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.

myFC Holding AB (publ) year-end report January - December 2018

Full year January - December 2018· Net sales amounted to SEK 577 thousand (337) · Operating profit amounted to SEK -91.2 million (-68.4) · Earnings per share amounted to SEK -1.63 (-2.25) Quarter October - December 2018 · Net sales amounted to SEK 110,000 (0) · Operating profit amounted to SEK -35.2 million (-38.7) · Earnings per share amounted to SEK -0.51 (-1.12) Significant events October - December 2018 · myFC showcases reference platform for smartphone integration and technology to protect from counterfeit fuel cards · myFC launches JAQ Hybrid in Japan

Year End Report 2018, Heliospectra AB ( publ)

GOTHENBURG, Sweden / SAN FRANCISCO, CA, February 22, 2019 – Heliospectra AB (publ) (OTCQB: HLSPY, FIRSTNORTH: HELIO), a world leader in intelligent lighting technology for greenhouse and controlled plant growth environments, are today presenting its Year-End Report for 2018.Financial Report October-December: · Net sales amounted to KSEK 11,083 (16,489)· Operating profit/loss was KSEK -12,020 (-7,478), involving a negative operating margin (neg)· Profit/loss after tax was KSEK -12,030 (-7,470) or SEK -0,34 (-0,21) per share· Operating cash flow was KSEK -4,790 (-3,

BONESUPPORT – Publication of a clinical study highlighting Vancomycin release from CERAMENT® V in major hip surgery

Lund, Sweden, 08.00 CET, 22 February 2019 – BONESUPPORT, an emerging leader in orthobiologics for the management of bone voids, today announces the publication of new data on antibiotic release from CERAMENT® V in a clinical study. The study ‘Vancomycin elution from a biphasic ceramic bone substitute’ is published in Bone Joint Research (Bone Joint Res 2019; 8: 1-6). Prof. Lars Lidgren from Lund University, senior author of the publication, commented: “This study represents an important milestone in understanding the antibiotic excretion kinetics of CERAMENT V in patients undergoing

Alimak Group: Interim report January – December 2018

Continued strong order intake · Strong order intake growth in the quarter for both Construction and Industrial. An organic growth of 5%, up to MSEK 1,214 (1,096) · Revenue for the quarter at MSEK 1,150 (1,050), an organic growth of 4% · EBITA adj. of MSEK 159 (145), representing a margin of 13.8% · Positive effects of integration starting to materialise Fourth quarter · Order intake increased by 11% to MSEK 1,214 (1,096) with an organic growth of 5% · Revenue increased by 10% to MSEK 1,150 (1,050) with an organic growth of 4% · EBITA adj. increased to MSEK 159 (

Castellum buys office buildings in central Gothenburg

Castellum has acquired the Gullbergsvass 1:2 and Gullbergsvass 1:12 office properties in central Gothenburg. Occupancy will occur March 1.The acquisition comprises two office properties at Lilla Bommen 5 and 6, with a total leasable area of approx. 16,595 sq.m. Acquisition price amounts to SEKm 867, including transaction costs. The office premises at Lilla Bommen 5 and 6 are located adjacent to Castellum’s existing office property at Lilla Bommen 4A-B. “Every day, 250,000 people go to work in our buildings. We strive continuously to develop workplaces in central locations, where

Lars Holmqvist nominated as chairman for Biovica

Lars Holmqvist is nominated to be elected as chairman for Biovica at an upcoming extra shareholders meeting on the 20th of March 2019. Lars will replace Göran Brorsson, who wishes to reduce his workload.Lars Holmqvist brings many years of experience and deep knowledge about the diagnostic business, which in combination with a strong international business network will add very valuable competence to Biovica and the ongoing commercialization process. Lars is one of the major shareholders in the company and also part of the Biovica Advisory Board since 2018. During his time as President

There are no items matching the current filter
There are no more items matching the current filter
Back to top